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Mitochondrial DNA (mtDNA) damage, predominantly encompassing point mutations, has been reported in a variety of cancers.
Here we present in human skin, the first detailed study of the distribution of multiple forms of mtDNA damage in nonmelanoma skin
cancer (NMSC) compared to histologically normal perilesional dermis and epidermis. We present the first entire spectrum of
deletions found between different types of skin tumours and perilesional skin. In addition, we provide the first quantitative data for the
incidence of the common deletion as well as the first report of specific tandem duplications in tumours from any tissue. Importantly,
this work shows that there are clear differences in the distribution of deletions between the tumour and the histologically normal
perilesional skin. Furthermore, DNA sequencing of four mutation ‘hotspot’ regions of the mitochondrial genome identified a
previously unreported somatic heteroplasmic mutation in an SCC patient. In addition, 81 unreported and reported homoplasmic
single base changes were identified in the other NMSC patients. Unlike the distribution of deletions and the heteroplasmic mutation,
these homoplasmic mutations were present in both tumour and perilesional skin, which suggests that for some genetic studies the
traditional use of histologically normal perilesional skin from NMSC patients may be limited. Currently, it is unclear whether mtDNA
damage has a direct link to skin cancer or it may simply reflect an underlying nuclear DNA instability.
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Each human cell contains hundreds to several thousand copies of
the 16.5kb human mitochondrial genome. This closed circular
genome encodes 13 polypeptides of the respiratory chain
complexes, as well as 22 transfer RNAs and two ribosomal RNAs
used in mitochondrial protein synthesis. Compared to nuclear
DNA, mitochondrial DNA (mtDNA) is highly susceptible to
damage because it is not associated with protective histones, it is
continually exposed to high levels of reactive oxygen species (ROS)
generated by oxidative phosphorylation, and there is a limited
capacity for mtDNA repair (Wallace, 1992). The complete mtDNA
sequence was determined in 1981 (Anderson et al, 1981) and
resequenced in 1999 (Andrews et al, 1999). A growing collection of
reported mtDNA mutations and rearrangements has been
associated with muscle and neurodegenerative diseases (Brierley
et al, 1998; Chinnery et al, 1999).
Mitochondria have been implicated in the carcinogenic process
because of their role in apoptosis (Kroemer and Reed, 2000) and
other aspects of tumour biology; in particular, somatic mutations
of mtDNA have been observed in a wide variety of human tumours
(reviewed in Penta et al, 2001). These findings together with the
fact that ultraviolet radiation (UVR) is important in the develop-
ment of nonmelanoma skin cancer (NMSC), and has been shown
to induce mtDNA damage in human skin (Birch-Machin et al,
1998; Ray et al, 2000), which led us to perform the first detailed
study of mtDNA damage in human NMSC. This type of skin cancer
consists of basal cell and squamous cell carcinoma (i.e. BCC and
SCC, respectively). BCCs are the commonest form of skin cancer
and occur mainly on sun-exposed body sites in elderly or middle-
aged subjects. They arise from the basal keratinocytes of the
epidermis, are locally invasive but rarely metastasise. SCCs are
derived from moderately differentiated keratinocytes. They mainly
occur in people over 55 years (y) of age and are found on sun-
exposed sites. In contrast to BCCs, the SCCs are derived from
precursor lesions such as actinic keratoses and importantly the
SCCs may metastasise.
This study is the first of its kind in the skin cancer literature as it
provides a detailed investigation of the different types of mtDNA
damage in both SCCs and BCCs compared to matched histologi-
cally normal perilesional tissue. We have investigated the entire
spectrum of large-scale deletions, the incidence of the common
deletion and tandem duplications, and the distribution of single
base changes in the mitochondrial genome.
MATERIALS AND METHODS
Patient samples and DNA extraction
Tumour and matched perilesional skin samples were taken with
informed consent from patients undergoing excision of an NMSC,
namely BCC (n¼5, age range 55–89y, mean 78y) or an SCC
(n¼5, age range 70–87y, mean 78y) at the Out-Patients Clinic,
Royal Victoria Infirmary, Newcastle, UK. The perilesional skin was
split into dermis and epidermis, and DNA extracted as described
previously (Birch-Machin et al, 1998).
Long template PCR
The deletion spectrum of large-scale deletions was investigated by
amplification of almost the entire 16.5kb mitochondrial genome in
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ytwo fragments, using long template PCR as described previously
(Ray et al, 2000). To ensure reproducibility and to prevent any
preferential amplification, the amount of DNA was standardised
for each sample.
3-primer PCR
A competitive, radioactive, PCR assay was used to quantify the
ratios of both deleted and wild-type mtDNA (Sciacco et al, 1994).
Wild-type and deleted mtDNAs are demonstrated by the presence
of a 755 and a 470bp PCR product, respectively.
‘Back-to-Back’ primer assay
This methodology has been previously described to screen for the
presence of tandem duplications in the D-loop (Brockington et al,
1993). The primers were L336 (nucleotide position (np) 336–355)
and H335 (np 335–316). Under the designated PCR conditions, the
orientation of these primers prevents the generation of a product
from wild-type mtDNA but permits a product from mitochondrial
genomes harbouring a 200bp or a 260bp tandem duplication in
the D-loop. The nucleotide positions of the tandem duplication
breakpoints have been previously described (Brockington et al,
1993; Lee et al, 1994).
DNA sequence analysis
Direct DNA sequencing of ND1, ND5, 16s RNA and the noncoding
D-loop region of the mitochondrial genome was performed as
previously described (Andrews et al, 1999). A review of the current
literature shows that these four mtDNA regions appear to be highly
susceptible to mutations (Penta et al, 2001). Automated DNA
sequencing was performed by MWG Biotech (Ebersberg, Ger-
many) and the resulting sequences compared to the revised
Cambridge mtDNA reference sequence (MITOMAP). Confirma-
tion of unreported base changes was performed by sequencing in
the reverse direction on independent PCR products.
RESULTS
The spectrum of large-scale mtDNA deletions
The deletion spectrum was investigated in the mitochondrial
genomes from the tumour samples and the histologically normal
perilesional dermis and epidermis samples from each NMSC
patient (total sample number is 30). Almost the entire mitochon-
drial genome was amplified in two fragments, namely 11 and
5.5kb. The spectrum of deletions is visualised as a DNA ladder of
PCR products on an agarose gel (Figure 1). The 11kb PCR
fragment encompasses the major deletion arc where the vast
majority of mtDNA deletions are reported (MITOMAP). There
were 20 different-sized deletions observed in both the tumour and
perilesional skin, with BCCs harbouring more deletions than SCCs
(Figure 1, A1 and A2, respectively). Within each triplet of patient
samples, the number of deletions in the epidermis never exceeded
that observed in the corresponding tumour and dermis. Interest-
ingly, the observed pattern of deletions in the tumour was often
very different compared to that observed in the matched
perilesional skin. Despite this, there is not a clear deletion pattern
that is characteristic of a particular tumour type.
The 5.5kb PCR fragment encompasses the minor deletion arc of
the mitochondrial genome, where fewer deletions are reported
(MITOMAP). A total of only four different-sized deletion species
were observed but, like the 11kb PCR results, the greatest number
of total deletions was observed in the BCC as opposed to the SCC
tumour samples (Figure 1, B1 and B2, respectively). Interestingly, a
PCR fragment of approximately 1.5kb (equivalent to a 4kb
deletion) was found to be common to all those samples that
harboured any deletion(s).
Quantification of the 4977bp common mtDNA deletion
Low levels of the common deletion, typically much less than 0.2%,
have been associated with ageing (Nagley and Wei, 1998). To
ensure that the effects of ageing do not confound our results for
the common deletion, we have presented data representing only
high levels (i.e. 42%) of deletion (a typical example is shown in
Figure 2A). We have shown previously that these high deletion
levels are not associated with chronological ageing, and this is
further confirmed by the data in Figure 2B that is arranged in
ascending order of age. The high levels of the common deletion
varied in the NMSC samples from 2.3 to 23.4% but were not
observed in the perilesional epidermis from the BCC patients. Four
of the 10 NMSC patients harbour high deletion levels in both the
tumour and the corresponding perilesional skin. In three of these
four patients, it was the tumour that harboured the highest level of
deletion by a factor of approximately 2–4-fold. Even in the
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Figure 1 MtDNA deletion spectrum of tumour and perilesional skin. A1
and A2: 11kb PCR profile for BCC and SCC, respectively. B1 and B2:5k b
PCR profile for BCC and SCC, respectively. Each panel of three lanes
represents a single NMSC patient; lane 1¼tumour, lane 2¼dermis, lane
3¼epidermis. The observed deletion profiles were reproducible over
three independent PCR experiments. Molecular weight markers (Hyper-
ladder I-range 10kb–200bp, Bioline Ltd, London UK) are the single lanes
at the ends of each row of panels.
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and perilesional skin were similarly high at 13.4 and 14.9%,
respectively. Interestingly, in a manner similar to the spectrum of
deletions, the observed patterns of the common deletion in the
tumour was often very different compared to that observed in the
matched perilesional skin.
Detection of tandem duplications within the D-loop
A total of four samples, representing three different NMSC
patients, were found to harbour a 200 or 260bp tandem
duplication. We found one BCC patient with a 260bp duplication
and three SCC patients with a 200bp duplication (Figure 2B). It has
been proposed previously that there is a link between the presence
of duplications and the common deletion (Nagley and Wei, 1998).
In this respect, three of the four samples with a duplication also
contained the common deletion in the corresponding sample.
MtDNA base changes
Comparative DNA sequence analysis was performed on four
regions of the mitochondrial genome from the tumour samples
and the histologically normal perilesional dermis and epidermis
samples from each NMSC patient. A total of 81 homoplasmic and
one heteroplasmic base substitutions were identified (Table 1). In
those cases where a homoplasmic base substitution was detected in
the tumour, the same DNA change was also observed in both the
perilesional dermis and epidermis. This contrasts with the
distribution of the deletions in these samples, as described in the
previous section.
Unlike the homoplasmic single base changes, the single
heteroplasmic base substitution was detected in the tumour only
(i.e. SCC from a 77-y-old patient). This is particularly interesting,
as it is strongly suggestive of a somatic mutation. It has been
previously shown that approximate levels of heteroplasmy can be
determined from the sequence electropherogram (Taylor et al,
2001). Using this methodology, an approximate value of 70%
mutant mtDNA in the SCC sample was estimated. The hetero-
plasmic change is a C to T transition at np 438 in the noncoding D-
loop (Figure 3), and furthermore it has not been previously
reported (MITOMAP). Similarly, 13 of the 81 homoplasmic base
changes have not been previously reported (Table 1A). Three of
these homoplasmic changes were located in the noncoding D-loop
and 10 in the coding region. Two of these 10 single base transitions
occur in the same BCC patient and alter amino acids within the
ND5 subunit of the complex I. The A to G transition at np 13528
changes a threonine to an alanine, whereas the C to T transition at
np 13565 alters a serine to phenylalanine.
Five of the 68 previously reported base changes (MITOMAP)
alter an amino acid in the ND5 (four out of five changes) and ND1
(one out of five changes) genes (Table 1B). The T to C transition at
np 4216 in the ND1 gene was in a BCC (89y) as well as in an SCC
(76y) patient. Two of the four base transitions within the ND5
gene at np 13105 and 13708 (Table 1B) are both present in the
same BCC patient (76y). The two remaining base transitions, at np
13117 and np 13934, were observed in a BCC patient (88y) and an
SCC patient (70y), respectively. Details of the 63 reported base
changes that do not alter an amino acid are summarised in
Table 1C. Further analysis of these and the other homoplasmic
base changes reported in Table 1 showed a lack of correlation with
age or category of NMSC (results not shown).
Duplication % Common Deletion
200bp nd 200bp 4.1 nd 12.3 76
nd nd nd nd 2.9 11.5 87
nd 200bp nd nd nd nd 81
nd nd nd nd nd nd 77
nd nd nd 2.1 2.3 nd 70 SCC
nd nd nd nd 14.9 13.4 89
nd 260bp nd nd 6.5 10.4 88
nd nd nd nd 6.8 nd 82
nd nd nd nd 23.4 nd 76
nd nd nd nd nd nd 55 BCC
E D T E D T
Age 
in 
years
Sample
B A T    D    E  
WT
CD
Figure 2 Quantification of the 4977bp common deletion and detection of tandem duplications. (A) An example of a phosphorimage from the 3-primer
PCR assay showing the PCR products that represent wild-type (WT) and deletion products (CD) in the tumour (T), and perilesional dermis and epidermis
(D and E, respectively) from the 89-y-old BCC patient detailed in part B.( B) The triplet of samples representing tumour (T), perilesional dermis (D) and
epidermis (E) from each NMSC patient were screened for the common deletion and duplications. nd¼not detected (duplications); levels below 2%
(common deletion).
C  C C  A   A C
     Dermis        Epidermis
C  C  C  A   A  C C  C  N A   A   C
  SCC
Figure 3 Somatic heteroplasmic mutation in skin mtDNA from a 77-y-
old SCC patient. A heteroplasmic C-T mutation at np 438 was identified
in the tumour only. The matched histologically normal perilesional
epidermis and dermis show only the wild-type sequence.
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For the first time in the skin cancer literature, we have presented a
detailed study of the distribution of multiple forms of mtDNA
damage in NMSC.
The spectrum of large-scale mtDNA deletions
This has been rarely investigated fully in previous tumour studies
and certainly not in skin (Penta et al, 2001). A total of 20 different
deletion species were observed in the major deletion arc and four
species were observed in the minor deletion arc. This contrasts
markedly with a single study in colorectal carcinomas, which
reported an absence of large-scale deletions using a similar long
PCR strategy (Penta et al, 2001). Although the absolute sample
numbers are small, our data clearly show that more deletions occur
in the skin from BCC rather than SCC patients. This may be
explained through different selection pressures exerted on the
deletions. For example, part of the process by which precursor
lesions progress to SCCs may represent a mtDNA mutation
Table 1 Summary of the 82 different mtDNA base changes identified in the tumour and perilesional skin samples. (A) Base changes that have been
previously unreported in the MITOMAP database. (B) Previously reported changes that alter an amino acid. (C) Previously reported synchronous changes
that do not alter the amino acid
Base change Map locus Amino-acid change Base change Map locus Amino-acid change
(A)
C438T
a OHR/LSP/TFL Noncoding C12348T ND5 F
A574G D-loop Noncoding C12633A ND5 F
C494A D-loop Noncoding C13251T ND5 F
T1694C RNR2 – A13528G ND5 Thr–Ala
A2294G RNR2 – C13565T ND5 Ser–Phe
G3531A ND1 – A13614G ND5 F
C4832T ND2 – A16183G HV1/7SDNA Noncoding
Base change Map locus Amino-acid change Base change Map locus Amino-acid change
(B)
T4216C ND1 Tyr–His G13708A ND5 Ala–Thr
A13105G ND5 Iso–Val C13934T ND5 Thr–Met
A13117G ND5 Iso–Val
Base change Map locus Base change Map locus
(C)
A73G HV2/7SDNA A12308G ND2
C150T HV2/OHR/7SDNA G12372A ND5
T152C HV2/OHR/7SDNA A12612G ND5
G185A HV2/OHR/7SDNA C12813T ND5
T195C HV2/OHR G13368A ND5
G228A HV2/OHR/CSB1 A14139G ND5
T239C HV2/TFX/OHR C14167T ND5
A263G HV2/OHR G15928A TT
C295T HV2/TFY/OHR C16069T 7SDNA
n(C)303 HV2/CSB2/TFY/OHR T16093C 7SDNA
n(C)311 HV2/CSB2/OHR T16126C 7SDNA
C456T D-loop A16162G HV1/TAS/7SDNA
C462T D-loop A16163G HV1/TAS/7SDNA
T489C D-loop A16166G HV1/TAS/7SDNA
C497T D-loop n(C)16184 HV1/7SDNA
G499A D-loop C16186T HV1/7SDNA
n(CA)514 D-loop T16189C HV1/7SDNA
n(C)568 D-loop T16209C HV1/7SDNA
G709A RNR1 T16224C HV1/7SDNA
T1189C RNR1 C16256T HV1/7SDNA
A1438G RNR1 C16286T HV1/7SDNA
A1811G RNR2 C16294T HV1/7SDNA
G1888A RNR2 T16304C HV1/7SDNA
A2706G RNR2 T16311C HV1/7SDNA
G3010A RNR2 A16343G HV1/7SDNA
T3290C TL1 T16356C HV1/7SDNA
A3480G ND1 T16362C HV1/7SDNA
G3915A ND1 G16390A 7SDNA
T4646C ND2 C16400T 7SDNA
T4703C ND2 A16482G 7SDNA
A4727G ND2 T16519C 7SDNA
A4769G ND2
The abbreviations for the map loci are detailed in MITOMAP.
aAll changes are homoplasmic and occur in both tumour and perilesional skin except this heteroplasmic somatic
mutation.
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mutations are selected against. Within each patient, the lowest
number of differently sized deletions was observed in the
epidermis, which agrees with our previous study that compared
dermis with epidermis from normal skin (Ray et al, 2000).
Interestingly, in contrast to the distribution of the homoplasmic
base substitutions described in our study, the observed pattern of
deletions in the tumour was often very different compared to that
observed in the matched perilesional skin. This may be suggestive
of different mutation and segregation events thereby giving rise to
different deletion spectra between the tumour and perilesional
skin. Interestingly, one of these deletions, derived from the minor
deletion arc and approximately 4kb in size, was present in every
skin sample that harboured a deletion. The identity of this deletion
may be the 3895bp species that has been reported in the minor
deletion arc spanning nucleotides 547–5443 (MITOMAP), and is
associated with Kearns Sayre Syndrome and Chronic Progressive
External Ophthalmoplegia.
The 4977bp common mtDNA deletion and tandem
duplications
The common deletion has been reported in 52% of 32 gastric
carcinomas, which is in marked contrast to the low incidence of
large-scale deletions in other tumours (Penta et al, 2001). The
authors of the gastric study have explained their observations by
the use of a more sensitive PCR technique, which detects low levels
of the common deletion (Maximo et al, 2001). It is well known,
however, that studies of low levels (i.e. typically o0.2%) of mtDNA
deletions can be confounded by the effects of ageing (Birch-
Machin et al, 1998; Nagley and Wei, 1998; Chinnery et al, 1999).
This scenario was avoided in our study by simply presenting only
high levels (42%) of the common deletion. We have previously
used this approach to show that this threshold value does not
reflect chronological ageing (Birch-Machin et al, 1998).
The present study is the first quantitative investigation of the
incidence of the common deletion in tumours. Higher deletion
levels in tumour were observed for three of the four patients who
harboured high levels of the deletion in both tumour and
perilesional skin. The observed pattern of the common deletion
contrasts once again with the distribution of the homoplasmic base
substitutions between tumour and perilesional skin. Unlike a
previous gastric study (Maximo et al, 2001), we could find no
evidence of an inverse relation between the incidence of the
common deletion and single base changes (results not shown).
There has been a suggested link between the presence of the
common deletion and tandem duplications in the D-loop
(Brockington et al, 1993). Two of the seven NMSC patients, who
harboured high levels of the common deletion, also contained
either a 200 or 260bp tandem duplication. To our knowledge, this
is the first report of tandem duplications of this type in tumours. It
is known that the tandem duplication encompasses several
regulatory regions, including the light- and heavy-strand promo-
ters, binding sites for mitochondrial transcription factor 1 and
most of the conserved sequence box II. The significance of these
findings is unclear until more work is performed within the field of
tandem duplications and skin (Krishnan and Birch-Machin, 2002).
MtDNA base changes
A total of 81 homoplasmic and one heteroplasmic single base
changes were identified in the skin from the NMSC patients.
Perhaps, the most interesting of these is the previously unreported
heteroplasmic transition at np 438 that was observed in an SCC but
was absent from the histologically normal perilesional tissue. This
is highly suggestive of a somatic mutation of the kind that has been
previously reported in other tumour types (Penta et al, 2001). The
somatic mutation occurs within a region of the D-loop, which
encompasses the origin of H-strand replication, the light-strand
promoter and a binding site for mitochondrial transcription factor
1. This suggests that the base alteration at np 438 may have a
profoundly deleterious effect on mitochondrial function. The
mechanism by which the heteroplasmic state of the np 438 has
reached a value of 70% is unknown. It has been shown that a
selective cellular growth advantage can be conferred by mutations
in the mitochondrial genome that can result not only in a high
level of heteroplasmy but also homoplasmy for the mutation
(Polyak et al, 1998). A contrasting model has recently been put
forward to explain this phenomenon (Coller et al, 2001). The
authors suggest that high levels of a heteroplasmic, and indeed a
homoplasmic, mitochondrial mutation in a tumour can result from
random segregation of mutant genomes in the many cell
generations that occur during tumour development.
Each of the 81 identified homoplasmic substitutions were
observed both in the tumour and perilesional skin. In all, 13 of
these 81 changes are unreported in the MITOMAP database. More
than half (44 out of 81) of the single base changes was observed in
the noncoding D-loop region. There are several possible explana-
tions for the presence of these 81 homoplasmic changes in both
tumour and perilesional skin. The first explanation may simply be
benign polymorphisms completely unrelated to the tumour
formation. In support of this, it has been suggested that
sequencing the mitochondrial genomes of random Europeans
would reveal approximately 10–12 single base changes between
individuals (personal communication, Dr Neil Howell, MitoKor,
San Diego, USA). An alternative explanation may be the fact that
all the skin samples used in our study are taken from constant sun-
exposed body sites and as such will have potentially received the
same mutagenic dose of UVR. This could be resolved through
sequencing mtDNA isolated from sun-protected sites, but current
ethical permission for the project does not allow the recall of the
skin cancer patients for this intended purpose.
We have identified seven base changes that introduce an amino-
acid change within the genes for ND5 (n¼6) and ND1 (n¼1).
Two of these at np 4216 (ND1) and 13708 (ND5) have been
correlated with Lebers Hereditary Optic Neuropathy (MitoAnaly-
zer; MITOMAP, National Institute of Standards and Technology,
Gaithersburg, MD, USA). In addition, two further base substitu-
tions at np 13528 and 13565 were previously unreported, and both
of these alter an amino acid with a polar side chain to one with a
nonpolar side chain. The functional significance, if any, of these
alterations is at present unclear, particularly as these amino acid
changes are present both in the tumour and the perilesional skin.
However, like all the other previous mtDNA and cancer studies in
the literature, the data are derived from automated DNA
sequencing that will reliably detect mutant loads only as low as
30% (Taylor et al, 2001). Therefore, below the 30% threshold value
there might be differences in mutagenic load between tumour and
perilesional skin. This is important for two reasons. First, there is a
threshold effect that describes the critical ratio between wild-type
and mutant mtDNA, which must be exceeded before phenotypic
expression of the mutant becomes apparent. For protein coding
mtDNA genes, such as those described in our study, the threshold
value is around 70% and above (Chomyn et al, 1992). Secondly,
given the large number of cell divisions necessary for tumour
development, estimated at 600 by Coller et al (2001), an alteration
in mitochondrial function that is exceedingly subtle in terms of its
biochemical or physiological manifestation may be all that is
necessary to alter significantly the probability of tumour formation
(Augenlicht and Heerdt, 2001).
An increased incidence of C insertions/deletions, within a
homopolymeric C-stretch between np 303 and 315 of the D-loop
(i.e. D310 tract), has been recently reported in several cancers
(Parrella et al, 2001; Sanchez-Cespedes et al, 2001). These studies
have proposed that instability in the D310 tract may be a useful
diagnostic marker for cancer development. In skin however, we
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in the tumour but also in the histologically normal perilesional
skin. Both skin sites receiving the same mutagenic dose of UVR
may explain this phenomenon. However, D310 instability is
observed regularly in mitochondrial genomes from noncancerous
skeletal muscle and brain (personal communication, Dr R Taylor,
Mitochondrial Gene Therapy Group, Newcastle, UK). Given these
observations, more work is therefore needed before D310
instability can be claimed to be a reliable and universal diagnostic
marker for cancer.
In conclusion, we provide the first detailed study of the
distribution of multiple forms of mtDNA damage in NMSC and
histologically normal perilesional tissue. We present the first entire
spectrum of deletions found between different types of skin
tumours and perilesional skin. In addition, we provide the first
quantitative data for the incidence of the common deletion as well
as the first report of specific tandem duplications in tumours from
any tissue. This work shows that there are differences in the
distribution of deletions between the tumour and the histologically
normal perilesional skin. DNA sequencing of four mutation
‘hotspot’ regions of the mitochondrial genome identified a
previously unreported somatic heteroplasmic mutation in an
SCC patient. In addition, 81 previously unreported and reported
homoplasmic single base changes were identified in the other
NMSC patients. Unlike the distribution of deletions and the
heteroplasmic mutation, these homoplasmic mutations were
present in both tumour and perilesional skin. This suggests that
the traditional use of histologically normal perilesional skin in
NMSC studies may have several limitations. This is important
when one considers that the majority of studies involving nuclear
DNA damage and skin cancer/skin disease often use perilesional
skin as a control tissue. Currently, it is unclear whether mtDNA
damage has a direct link to skin cancer or it may simply reflect an
underlying nuclear DNA instability.
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